Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 17Neoplasm Metastasis 8Carcinoma, Non-Small-Cell Lung 6Glioblastoma 5Triple Negative Breast Neoplasms 4Lymphoma, Mantle-Cell 4Lymphoma, Follicular 4Colorectal Neoplasms 4Recurrence 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Neoplasms 3Lymphoma, Large B-Cell, Diffuse 3Squamous Cell Carcinoma of Head and Neck 2Solid Tumors 2Lymphoma 2Lung Neoplasms 2Leukemia, Myeloid, Acute 2Hereditary Sensory and Autonomic Neuropathies 2Head and Neck Neoplasms 2Endometrial Neoplasms 2Brain Neoplasms 2Waldenstrom Macroglobulinemia 1Unspecified Adult Solid Tumor, Protocol Specific 1Tongue Neoplasms 1Thymoma 1Stomach Neoplasms 1Salivary Gland Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pre-menopausal Breast Cancer 1

Interventions

Rituximab 52Cyclophosphamide 42fludarabine phosphate 41Peripheral Blood Stem Cell Transplantation 41Whole-Body Irradiation 26Mycophenolic Acid 25Cyclosporine 21Bortezomib 21Dexamethasone 19Busulfan 18Tacrolimus 17Etoposide 17Filgrastim 15Antilymphocyte Serum 14Methotrexate 13Melphalan 13ibrutinib 12Radiotherapy 11Calcium Dobesilate 9Sirolimus 8Lenalidomide 8Cyclosporins 8Methylprednisolone 7Flow Cytometry 7Everolimus 7Carboplatin 7ibritumomab tiuxetan 6zanubrutinib 5fludarabine 5Transplantation 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Waldenstrom Macroglobulinemia × NVP-BKM120 × Clear all
NCT02049541 2022-06-30

Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
18 enrolled
Lymphoid

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡